In the September issue of Pharmaceutical Executive, Lev Gerlovin addresses four main questions that US drugmakers must answer to cope with the evolving payer landscape given rising drug prices. To read the article, click the link below.
Navigating payer challenges in rare disease
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...